doi: 10.3390/jcm12010145 Summary Keywords type 2 diabetes, chronic kidney disease, GLP-1 receptor agonists, semaglutide, glycosylated hemoglobin, weight loss, estimated glomerular filtration rate, urinary albumin-to-creatinine ratio Citation Garca de Lucas MD, Caballero I, Fernndez-Garca JC, Domnguez-Rodrguez M, Moreno-Moreno P, Jimnez-Milln A, Botana-Lpez M, Avils B, Merino-Torres JF, Soto A, Tejera C and Morales C (2023) Influence of chronic kidney disease and its severity on the efficacy of semaglutide in type 2 diabetes patients: a multicenter real-world study
How PlexusDx Supports a More Personalized Approach The PlexusDx Precision Peptide Genetic Test reveals predispositions in immune-metabolic pathwaysincluding variants in GLP1R, GIPR, and inflammatory markersthat may help provide context for how your body responds to viral challenge while on GLP-1 therapy
doi: 10.1093/eurheartj/ehad192 [DOI] [PubMed] [Google Scholar] 15.American Diabetes Association Professional Practice Committee
If you are a competitive athlete: Verify current WADA or sport-specific governing body status